Mary Albrecht is an Infectious Disease physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
110 Francis Street
Beth Israel Deaconess Medical Center
Boston, MA 02215
Telephone
617-632-7706Registry record last updated 8 Jul 2007.
Clinical trials
- Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Protease Inhibitor17%Symtuza68%Ritonavir32%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor12.5%Triumeq100%Part D<11 patients+ 10 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1999–2002 per NIH RePORTER. The latest:
- ACTG 5025--HYDROXYUREA IN POTENT ANTIRETROVIRAL THERAPY
Beth Israel Deaconess Medical Center
FY2002M01RR001032 - ACTG 384: PROTEASE INHIBITOR &NON NUCLEOSIDE REVERSE TRANSCRIPTASE I
Beth Israel Deaconess Medical Center
FY2002M01RR001032 - ACTG 388: EFZ OR NFV IN COMBINATION W/ FDC 3TC/ZDV &IDV
Beth Israel Deaconess Medical Center
FY2002M01RR001032
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”